{"entity":{"type":"insider","cik":"0001898314","url":"/insider/0001898314","json_url":"/insider/0001898314.json","name":"Klee Justin B.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":18,"n_filings":14,"first":"2023-01-10","last":"2026-03-04","span_basis":"filed_date"},"name_variants":[{"name":"Klee Justin B.","source":"filing","n_filings":14,"first_seen":"2023-01-10","last_seen":"2026-03-04"}],"transactions":[{"id":5809650,"accession":"0001193125-26-091443","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-091443","line_url":"/filing/0001193125-26-091443#line-1","is_derivative":false,"issuer_cik":"0001658551","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001658551","owner_cik":"0001898314","owner_name":"Klee Justin B.","owner_display_name":"Klee Justin B.","owner_url":"/insider/0001898314","role":"Director, Officer (Co-Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Co-Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":29282.0,"shares_display":"29,282","price_per_share":14.4717,"price_display":"14.47","price_state":"stated","total_value":423760.3194,"total_display":"423,760.32","total_whole":"423,760","shares_owned_after":3334616.0,"shares_owned_after_display":"3,334,616","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-02","filed_date":"2026-03-04","scope":"insider"},{"id":6036189,"accession":"0001193125-26-037544","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-037544","line_url":"/filing/0001193125-26-037544#line-1","is_derivative":false,"issuer_cik":"0001658551","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001658551","owner_cik":"0001898314","owner_name":"Klee Justin B.","owner_display_name":"Klee Justin B.","owner_url":"/insider/0001898314","role":"Director, Officer (Co-Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Co-Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15500.0,"shares_display":"15,500","price_per_share":14.685,"price_display":"14.68","price_state":"stated","total_value":227617.5,"total_display":"227,617.50","total_whole":"227,618","shares_owned_after":3363898.0,"shares_owned_after_display":"3,363,898","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-02-02","filed_date":"2026-02-04","scope":"insider"},{"id":5770343,"accession":"0001193125-26-017056","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-26-017056","line_url":"/filing/0001193125-26-017056#line-4","is_derivative":false,"issuer_cik":"0001658551","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001658551","owner_cik":"0001898314","owner_name":"Klee Justin B.","owner_display_name":"Klee Justin B.","owner_url":"/insider/0001898314","role":"Director, Officer (Co-Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Co-Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1995.0,"shares_display":"1,995","price_per_share":13.8853,"price_display":"13.89","price_state":"stated","total_value":27701.1735,"total_display":"27,701.17","total_whole":"27,701","shares_owned_after":3379398.0,"shares_owned_after_display":"3,379,398","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-16","filed_date":"2026-01-20","scope":"insider"},{"id":5770339,"accession":"0001193125-26-017056","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-26-017056","line_url":"/filing/0001193125-26-017056#line-2","is_derivative":false,"issuer_cik":"0001658551","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001658551","owner_cik":"0001898314","owner_name":"Klee Justin B.","owner_display_name":"Klee Justin B.","owner_url":"/insider/0001898314","role":"Director, Officer (Co-Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Co-Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":136193.0,"shares_display":"136,193","price_per_share":13.5827,"price_display":"13.58","price_state":"stated","total_value":1849868.6611,"total_display":"1,849,868.66","total_whole":"1,849,869","shares_owned_after":3378546.0,"shares_owned_after_display":"3,378,546","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-15","filed_date":"2026-01-20","scope":"insider"},{"id":6000714,"accession":"0001193125-26-007664","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-007664","line_url":"/filing/0001193125-26-007664#line-1","is_derivative":false,"issuer_cik":"0001658551","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001658551","owner_cik":"0001898314","owner_name":"Klee Justin B.","owner_display_name":"Klee Justin B.","owner_url":"/insider/0001898314","role":"Director, Officer (Co-Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Co-Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7715.0,"shares_display":"7,715","price_per_share":11.0939,"price_display":"11.09","price_state":"stated","total_value":85589.4385,"total_display":"85,589.44","total_whole":"85,589","shares_owned_after":3317586.0,"shares_owned_after_display":"3,317,586","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-06","filed_date":"2026-01-08","scope":"insider"},{"id":4372177,"accession":"0001193125-25-228343","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-228343","line_url":"/filing/0001193125-25-228343","is_derivative":false,"issuer_cik":"0001658551","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001658551","owner_cik":"0001898314","owner_name":"Klee Justin B.","owner_display_name":"Klee Justin B.","owner_url":"/insider/0001898314","role":"Director, Officer (Co-Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Co-Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":29975.0,"shares_display":"29,975","price_per_share":14.37705154295246,"price_display":"14.38","price_state":"stated","total_value":430952.12,"total_display":"430,952.12","total_whole":"430,952","shares_owned_after":3325501.0,"shares_owned_after_display":"3,325,501","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-30","filed_date":"2025-10-02","scope":"insider","n_lines":2},{"id":4495701,"accession":"0000950170-25-049495","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-049495","line_url":"/filing/0000950170-25-049495#line-1","is_derivative":false,"issuer_cik":"0001658551","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001658551","owner_cik":"0001898314","owner_name":"Klee Justin B.","owner_display_name":"Klee Justin B.","owner_url":"/insider/0001898314","role":"Director, Officer (Co-Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Co-Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21490.0,"shares_display":"21,490","price_per_share":3.4646,"price_display":"3.46","price_state":"stated","total_value":74454.254,"total_display":"74,454.25","total_whole":"74,454","shares_owned_after":3355276.0,"shares_owned_after_display":"3,355,276","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-31","filed_date":"2025-04-02","scope":"insider"},{"id":4194314,"accession":"0000950170-25-033725","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-033725","line_url":"/filing/0000950170-25-033725#line-1","is_derivative":false,"issuer_cik":"0001658551","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001658551","owner_cik":"0001898314","owner_name":"Klee Justin B.","owner_display_name":"Klee Justin B.","owner_url":"/insider/0001898314","role":"Director, Officer (Co-Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Co-Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4595.0,"shares_display":"4,595","price_per_share":3.152,"price_display":"3.15","price_state":"stated","total_value":14483.44,"total_display":"14,483.44","total_whole":"14,483","shares_owned_after":3196648.0,"shares_owned_after_display":"3,196,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-03","filed_date":"2025-03-05","scope":"insider"},{"id":4748706,"accession":"0000950170-25-014607","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-014607","line_url":"/filing/0000950170-25-014607#line-1","is_derivative":false,"issuer_cik":"0001658551","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001658551","owner_cik":"0001898314","owner_name":"Klee Justin B.","owner_display_name":"Klee Justin B.","owner_url":"/insider/0001898314","role":"Director, Officer (Co-Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Co-Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11855.0,"shares_display":"11,855","price_per_share":3.4672,"price_display":"3.47","price_state":"stated","total_value":41103.656,"total_display":"41,103.66","total_whole":"41,104","shares_owned_after":3164933.0,"shares_owned_after_display":"3,164,933","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-03","filed_date":"2025-02-05","scope":"insider"},{"id":4375548,"accession":"0000950170-25-003533","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-003533","line_url":"/filing/0000950170-25-003533#line-1","is_derivative":false,"issuer_cik":"0001658551","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001658551","owner_cik":"0001898314","owner_name":"Klee Justin B.","owner_display_name":"Klee Justin B.","owner_url":"/insider/0001898314","role":"Director, Officer (Co-Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Co-Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7471.0,"shares_display":"7,471","price_per_share":4.0425,"price_display":"4.04","price_state":"stated","total_value":30201.5175,"total_display":"30,201.52","total_whole":"30,202","shares_owned_after":3176788.0,"shares_owned_after_display":"3,176,788","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-06","filed_date":"2025-01-08","scope":"insider"},{"id":2951835,"accession":"0000950170-24-111812","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-111812","line_url":"/filing/0000950170-24-111812#line-1","is_derivative":false,"issuer_cik":"0001658551","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001658551","owner_cik":"0001898314","owner_name":"Klee Justin B.","owner_display_name":"Klee Justin B.","owner_url":"/insider/0001898314","role":"Director, Officer (Co-Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Co-Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18589.0,"shares_display":"18,589","price_per_share":3.197,"price_display":"3.20","price_state":"stated","total_value":59429.033,"total_display":"59,429.03","total_whole":"59,429","shares_owned_after":3120569.0,"shares_owned_after_display":"3,120,569","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-30","filed_date":"2024-10-02","scope":"insider"},{"id":2459244,"accession":"0000950170-24-027922","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-027922","line_url":"/filing/0000950170-24-027922#line-1","is_derivative":false,"issuer_cik":"0001658551","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001658551","owner_cik":"0001898314","owner_name":"Klee Justin B.","owner_display_name":"Klee Justin B.","owner_url":"/insider/0001898314","role":"Director, Officer (Co-Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Co-Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4135.0,"shares_display":"4,135","price_per_share":18.7279,"price_display":"18.73","price_state":"stated","total_value":77439.8665,"total_display":"77,439.87","total_whole":"77,440","shares_owned_after":2959308.0,"shares_owned_after_display":"2,959,308","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-05","filed_date":"2024-03-07","scope":"insider"},{"id":2673037,"accession":"0000950170-24-003985","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-003985","line_url":"/filing/0000950170-24-003985#line-1","is_derivative":false,"issuer_cik":"0001658551","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001658551","owner_cik":"0001898314","owner_name":"Klee Justin B.","owner_display_name":"Klee Justin B.","owner_url":"/insider/0001898314","role":"Director, Officer (Co-Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Co-Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5841.0,"shares_display":"5,841","price_per_share":16.3281,"price_display":"16.33","price_state":"stated","total_value":95372.4321,"total_display":"95,372.43","total_whole":"95,372","shares_owned_after":2836776.0,"shares_owned_after_display":"2,836,776","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-09","filed_date":"2024-01-11","scope":"insider"},{"id":8457351,"accession":"0000899243-23-009182","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-23-009182","line_url":"/filing/0000899243-23-009182","is_derivative":false,"issuer_cik":"0001658551","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001658551","owner_cik":"0001898314","owner_name":"Klee Justin B.","owner_display_name":"Klee Justin B.","owner_url":"/insider/0001898314","role":"Director, Officer (Co-Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Co-Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":31.86236197,"price_display":"31.86","price_state":"stated","total_value":3186236.197,"total_display":"3,186,236.20","total_whole":"3,186,236","shares_owned_after":2796062.0,"shares_owned_after_display":"2,796,062","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-16","filed_date":"2023-03-20","scope":"insider","n_lines":2},{"id":8669035,"accession":"0000899243-23-001517","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-23-001517","line_url":"/filing/0000899243-23-001517","is_derivative":false,"issuer_cik":"0001658551","issuer_name":"Amylyx Pharmaceuticals, Inc.","issuer_ticker":"AMLX","issuer_name_source":null,"issuer_url":"/issuer/0001658551","owner_cik":"0001898314","owner_name":"Klee Justin B.","owner_display_name":"Klee Justin B.","owner_url":"/insider/0001898314","role":"Director, Officer (Co-Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Co-Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5968.0,"shares_display":"5,968","price_per_share":36.29848367962467,"price_display":"36.30","price_state":"stated","total_value":216629.3506,"total_display":"216,629.35","total_whole":"216,629","shares_owned_after":2894463.0,"shares_owned_after_display":"2,894,463","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-06","filed_date":"2023-01-10","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":18,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":18,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":18},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001658551","name":"Amylyx Pharmaceuticals, Inc.","url":"/issuer/0001658551","role":"Director, Officer (Co-Chief Executive Officer)","n_filings":14,"first_seen":"2023-01-10","last_seen":"2026-03-04"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001898314","retrieved_at":"2026-08-26T19:23:23+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}